Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, Daniel Aletaha, Thomas Dörner, Roy Fleischmann, Iain McInnes, Jette Primdahl, N Sattar, Yoshiya Tanaka, Michael Trauner, Kevin Winthrop, Maarten de Wit, Johan Askling, Xenofon Baraliakos, Wolf‐Henning Boehncke, Paul Emery, Laure Gossec, John D. Isaacs, Maria Theresa Krauth, Eun Bong Lee, Walter P. Maksymowych, Janet Pope, Marieke Voshaar, Karen Schreiber, Stefan Schreiber, Tanja Stamm, Peter C. Taylor, Tsutomu Takeuchi, Lai‐Shan Tam, Filip Van den Bosch, René Westhovens, Markus Zeitlinger, Josef S Smolen
Abstract
In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy, a multidisciplinary taskforce was assembled, encompassing patients, health care professionals, and clinicians with expertise in JAKi therapy across specialties. This taskforce, informed by two comprehensive systematic literature reviews, undertook the objective to update the previous expert consensus for using JAKi developed in 2019. The taskforce deliberated on overarching principles, indications, dosage and comedication strategies, warnings and contraindications, screening protocols, monitoring recommendations, and adverse effect profiles. The methodology was based on the European Alliance of Associations for Rheumatology standard operating procedures, with voting on these important elements. Furthermore, an updated research agenda was proposed. The task force did not address when a JAKi should be prescribed but rather considerations once this decision has been made. This update aimed to equip clinicians with the necessary knowledge and guidance for the efficient and safe administration of this expanding and significant class of drugs.